FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy

King regoups after patent fight loss

Tools

Please, please, please change your mind: Yesterday, King Pharmaceuticals lost its fight with Indian generics maker Lupin when a federal appeals court invalidated the patent on Altace. Today, King says it's asking for a rehearing. The court misapplied precedent and relied on factual inaccuracies, the company says.

The high blood pressure remedy was supposed to be safe through October 2008. With sales of $900 million in the 12 months ended June 30, it makes up about one-third of King's revenues--so you can understand the company's consternation. The company had planned to launch a tweaked version of Altace early next year as a sort of trawling net for BP patients tempted to switch to the generic.

- see the release for more info

Related Articles:
King bails on Palatin's FSM program. Report
FDA rejects King's Altace. Report

More stories about Generics   Patent   Patent news   King Pharmaceuticals   Altace   Lupin  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 11 + 22?
To combat spam, please solve the math question above.